NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 54-59, 2026

©NIJSES PUBLICATIONS

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.5459

Nano-Enabled Regulation of Adipokines and Cytokine Signaling in Obesity-Induced Inflammatory Pathways

Winniefred Nankya

Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug

ABSTRACT

Obesity is characterized by an imbalance in energy homeostasis, leading to an increase in adiposity and the subsequent release of adipokines and cytokines, which play a pivotal role in the pathogenesis of obesity-associated inflammation. This inflammation is a critical factor in the development of obesity-related comorbidities, such as type 2 diabetes, cardiovascular disease, and certain cancers. Recent advancements in nanotechnology have opened new therapeutic avenues to regulate adipokines and cytokines, offering promising strategies for modulating obesity-induced inflammatory pathways. Nano-enabled approaches, including nanomaterials, nanoparticles, and nanostructures, have demonstrated their potential in enhancing the bioavailability, stability, and targeted delivery of therapeutic agents. Moreover, these nanomaterials can interact with adipocytes, immune cells, and the extracellular matrix to modulate the expression and secretion of pro-inflammatory adipokines and cytokines. This review explores the current understanding of nano-enabled regulation of adipokines and cytokine signaling, highlighting the mechanisms through which nanoparticles influence key inflammatory pathways. Furthermore, the article examines the applications of nano-based therapies in controlling obesity-induced inflammation and their potential for mitigating obesity-related diseases. Finally, the challenges, limitations, and future directions of nanotechnology in obesity management are discussed.

Keywords: Obesity, Adipokines, Cytokines, Nano-therapy, Inflammation

INTRODUCTION

Obesity, a global health crisis, is associated with numerous metabolic and cardiovascular diseases. Its increasing prevalence is a consequence of altered energy balance, primarily resulting from excessive caloric intake and reduced physical activity[1–3]. While obesity is often regarded as a result of nutrient excess, its underlying mechanisms are far more complex, involving genetic, environmental, and metabolic factors. One of the central features of obesity is the chronic low-grade inflammation that arises from the expansion of adipose tissue[4–7]. This inflammation is primarily mediated by the secretion of bioactive molecules, including adipokines and cytokines, from adipocytes and infiltrating immune cells[8, 9].

Adipokines, such as leptin, adiponectin, and resistin, are secreted by adipocytes and play crucial roles in regulating energy balance, insulin sensitivity, and immune responses[10, 11]. In obesity, the dysregulated secretion of these adipokines contributes to insulin resistance, endothelial dysfunction, and the promotion of inflammation. Cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), are secreted by adipocytes and immune cells, further exacerbating systemic inflammation and tissue damage[9, 12]. The interplay between adipokines and cytokines drives the inflammatory cascade that characterizes obesity-related diseases.

Recently, nanotechnology has emerged as a promising tool for regulating adipokines and cytokine signaling in obesity. Nano-enabled therapies offer a unique opportunity to modulate these signaling pathways by delivering therapeutic agents more effectively and selectively to the adipose tissue and other inflammatory sites.

Nanoparticles, nanomaterials, and nanostructures have demonstrated the ability to enhance drug stability, improve tissue targeting, and facilitate controlled release, all of which are critical in managing obesity-induced inflammation[13–17]. This review aims to provide a comprehensive understanding of the role of nano-enabled approaches in regulating adipokines and cytokines in obesity-induced inflammation. We will explore the mechanisms by which nanomaterials interact with adipocytes and immune cells, modulate adipokine and cytokine production, and influence the inflammatory pathways that contribute to obesity-related diseases. Additionally, we will discuss the current state of research, the potential clinical applications, and the challenges and limitations that need to be addressed for the successful translation of nano-based therapies into clinical practice.

2. Pathophysiology of Obesity-Induced Inflammation

Obesity-induced inflammation results from the complex interaction between adipocytes, immune cells, and the extracellular matrix (ECM) in expanded adipose tissue. In a healthy state, adipose tissue acts as an endocrine organ, releasing adipokines that regulate energy homeostasis, glucose metabolism, and immune responses[12, 18–20]. However, during obesity, the excessive accumulation of fat leads to hypertrophy of adipocytes, which can disrupt their normal function and trigger inflammatory processes.

The expansion of adipose tissue is accompanied by an infiltration of macrophages, which play a central role in the inflammatory response[21]. These macrophages secrete pro-inflammatory cytokines, such as TNF-α, IL-6, and MCP-1, which further promote adipocyte dysfunction and the recruitment of additional immune cells[19, 22, 23]. This chronic inflammatory environment is characterized by increased oxidative stress, endothelial dysfunction, and insulin resistance. The inflammatory cytokines released by adipocytes and immune cells contribute to the systemic spread of inflammation, affecting various organs and tissues, including the liver, muscle, and pancreas.

Increased levels of pro-inflammatory cytokines are closely linked to the development of insulin resistance, a hallmark of obesity-related metabolic diseases. Cytokines such as TNF-α and IL-6 interfere with insulin signaling pathways, impairing glucose uptake by peripheral tissues. Additionally, these cytokines stimulate the release of adipokines, such as leptin, which, in turn, exacerbate the inflammatory response[24–26]. The vicious cycle of inflammation, insulin resistance, and adipokine dysregulation plays a crucial role in the progression of obesity-related diseases[27].

3. Nano-Enabled Regulation of Adipokines

Adipokines are critical regulators of energy balance, immune function, and inflammation. In obesity, the dysregulation of adipokine secretion contributes to the development of insulin resistance and systemic inflammation[10, 28]. Nano-enabled approaches have shown promise in modulating adipokine signaling by improving the delivery of therapeutic agents to adipocytes and immune cells.

Nanoparticles, such as liposomes, micelles, and polymeric nanoparticles, can be designed to encapsulate therapeutic agents, ensuring their stability and controlled release. These nanoparticles can be engineered to target specific receptors on adipocytes, facilitating the targeted delivery of drugs that regulate adipokine secretion[17, 29, 30]. For example, nanoparticles loaded with anti-inflammatory agents can reduce the secretion of pro-inflammatory adipokines, such as TNF-α and IL-6, while promoting the release of anti-inflammatory adipokines like adiponectin[31–33]. Moreover, nano-based therapies can modulate the expression of adipokine receptors on adipocytes, thereby altering the cellular response to these signaling molecules[34, 35]. This can help restore the balance of adipokine secretion and mitigate the inflammatory effects associated with obesity. For instance, nanoparticles that activate the adiponectin receptor may enhance insulin sensitivity and reduce inflammation in adipose tissue, muscle, and liver.

4. Nano-Enabled Regulation of Cytokine Signaling

Cytokines play a pivotal role in obesity-induced inflammation by promoting immune cell recruitment, endothelial dysfunction, and insulin resistance. Nano-enabled approaches offer a novel strategy to regulate cytokine signaling, either by inhibiting the production of pro-inflammatory cytokines or by enhancing the activity of anti-inflammatory cytokines[12, 36]. Nanoparticles can be designed to deliver cytokine inhibitors or cytokine-neutralizing agents directly to inflammatory sites, such as adipose tissue, where they can block the activity of pro-inflammatory cytokines like TNF-α, IL-6, and MCP-1. Additionally, nanomaterials can be used to deliver RNA-based therapeutics, such as small interfering RNA (siRNA), to selectively silence the expression of genes encoding for these cytokines[37–40].

Nanoparticles can also be employed to enhance the activity of anti-inflammatory cytokines, such as interleukin-10 (IL-10), by delivering cytokine mimetics or gene therapies that promote their expression[29, 30, 35, 41]. By targeting specific signaling pathways involved in cytokine production, nano-based therapies can help restore immune homeostasis and reduce the chronic inflammation that characterizes obesity.

5. Nano-Based Delivery Systems for Obesity-Induced Inflammation

The success of nano-based therapies depends on the development of efficient delivery systems that can target adipose tissue and other inflammatory sites with high precision. Various nano-carriers, including liposomes, dendrimers, and solid lipid nanoparticles, have been developed to enhance drug delivery and minimize off-target effects[42].

One of the key advantages of nano-based delivery systems is their ability to improve the bioavailability and stability of therapeutic agents, particularly those that are poorly soluble or rapidly degraded in the body[43]. Additionally, the surface properties of nanoparticles can be tailored to facilitate cellular uptake and enhance tissue targeting. For instance, nanoparticles can be functionalized with ligands or antibodies that specifically bind to receptors on adipocytes or immune cells, ensuring targeted delivery to sites of inflammation[38, 41, 44]. Moreover, nano-based delivery systems can provide sustained release of therapeutic agents, allowing for prolonged therapeutic effects and reducing the need for frequent dosing[44]. This controlled release is particularly important in the context of obesity, where continuous modulation of adipokine and cytokine signaling is necessary to manage chronic inflammation.

6. Challenges and Limitations of Nano-Based Therapies

Despite the promising potential of nano-based therapies, several challenges must be addressed before they can be translated into clinical practice for the treatment of obesity-induced inflammation[45-48]. One major concern is the potential toxicity of nanoparticles, which may accumulate in organs such as the liver and spleen, leading to adverse effects. The long-term safety of nano-based therapies remains a critical issue, and extensive preclinical and clinical studies are required to assess the biocompatibility and clearance of these nanoparticles[49-52].

Another challenge is the complexity of obesity-induced inflammation, which involves a diverse array of immune cells, adipokines, and cytokines. Designing nanoparticles that can effectively target and modulate all of these components is a daunting task. Additionally, the heterogeneity of obesity in terms of genetics, diet, and comorbidities complicates the development of universal nano-therapies[46, 47,48-52]. Furthermore, the scalability and cost of producing nano-based therapies remain significant hurdles. The synthesis of nanoparticles is often labor-intensive and costly, which could limit their widespread use in clinical settings.

7. Future Directions and Clinical Implications

The future of nano-based therapies for obesity-induced inflammation holds great promise, with ongoing research focused on improving the design and functionality of nanoparticles. Advancements in nanomaterial synthesis, surface modification, and targeted delivery will likely lead to more efficient and selective therapies. Additionally, the integration of nano-based therapies with other treatment modalities, such as diet modification and exercise, could enhance their therapeutic efficacy.

In terms of clinical applications, nano-based therapies could be used in conjunction with traditional anti-inflammatory drugs to provide a multi-faceted approach to managing obesity-induced inflammation. Personalized medicine, where nano-therapies are tailored to an individual's genetic and metabolic profile, could further enhance treatment outcomes. Moreover, the combination of nanotechnology with other emerging therapies, such as gene editing and immunotherapy, may offer new avenues for treating obesity-related diseases. The ability to regulate adipokines and cytokines at the molecular level could provide a powerful tool for modulating inflammation and reversing the metabolic dysfunction associated with obesity.

CONCLUSION

Nano-enabled therapies represent a promising approach for regulating adipokine and cytokine signaling in obesity-induced inflammation. By improving the delivery, bioavailability, and targeted action of therapeutic agents, nanomaterials have the potential to modulate the inflammatory pathways that contribute to obesity-related diseases. Although challenges remain, including concerns about safety, toxicity, and scalability, ongoing advancements in nanotechnology offer exciting opportunities for the development of novel treatments for obesity. As research progresses, nano-based therapies may complement existing treatments and provide more effective strategies for managing obesity and its associated comorbidities.

REFERENCES

1. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov. Oncol. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
2. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
3. Bays, H.E., Kirkpatrick, C., Maki, K.C., Toth, P.P., Morgan, R.T., Tondt, J., Christensen, S.M., Dixon, D., Jacobson, T.A.: Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obes. Pillars. 10, 100108 (2024). https://doi.org/10.1016/j.obpill.2024.100108
4. Uti, D.E., Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. Pharm. Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086

6. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
7. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
8. Almohaimeed, H.M., Almars, A.I., Tounsi, W.A., Mohammedsaleh, Z.M., Panigrahi, R., Singh, I., Singh, S., Dhara, B., Uti, D.E.: Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases. J. Clin. Immunol. 46, 3 (2025). https://doi.org/10.1007/s10875-025-01965-0
9. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
10. Roy, P.K., Islam, J., Lalhlenmawia, H.: Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance. Egypt. Heart J. 75, 24 (2023). https://doi.org/10.1186/s43044-023-00352-7
11. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
12. Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
13. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
14. Gholami, A., Mohkam, M., Soleimanian, S., Sadraeian, M., Lauto, A.: Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsyst. Nanoeng. 10, 1–43 (2024). https://doi.org/10.1038/s41378-024-00743-z
15. Mansoori, G.-A.: The Role of Nanotechnology to Combat Major Recent Worldwide Challenges. Curr. Appl. Sci. 1, 1–8 (2023). https://doi.org/10.22034/cas.2021.144244
16. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
17. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
18. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
19. Guerreiro, V.A., Carvalho, D., Freitas, P.: Obesity, Adipose Tissue, and Inflammation Answered in Questions. J. Obes. 2022, 2252516 (2022). https://doi.org/10.1155/2022/2252516
20. Kang, H.S., Liao, G., DeGraff, L.M., Gerrish, K., Bortner, C.D., Garantziotis, S., Jetten, A.M.: CD44 Plays a Critical Role in Regulating Diet-Induced Adipose Inflammation, Hepatic Steatosis, and Insulin Resistance. PLOS ONE. 8, e58417 (2013). https://doi.org/10.1371/journal.pone.0058417
21. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
22. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
23. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat. Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
24. Mittal, B.: Subcutaneous adipose tissue & visceral adipose tissue. Indian J. Med. Res. 149, 571–573 (2019). https://doi.org/10.4103/ijmr.IJMR_1910_18
25. Song, A., Dai, W., Jang, M.J., Medrano, L., Li, Z., Zhao, H., Shao, M., Tan, J., Li, A., Ning, T., Miller, M.M., Armstrong, B., Huss, J.M., Zhu, Y., Liu, Y., Gradinaru, V., Wu, X., Jiang, L., Scherer, P.E., Wang,

Q.A.: Low- and high-thermogenic brown adipocyte subpopulations coexist in murine adipose tissue. J. Clin. Invest. 130, 247–257 (2020). https://doi.org/10.1172/JCI129167
26. Trayhurn, P.: Brown Adipose Tissue—A Therapeutic Target in Obesity? Front. Physiol. 9, 1672 (2018). https://doi.org/10.3389/fphys.2018.01672
27. Eu, A., He, A., Dc, O., Pn, O., Uc, A., Ap, E.: Maternal Nutrition, Toxicants, and Epigenetic Programming of Obesity Across Generations. PubMed. (2025)
28. Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K.: Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97 (2011). https://doi.org/10.1038/nri2921
29. Hayward, S.L., Wilson, C.L., Kidambi, S.: Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells. Oncotarget. 7, 34158–34171 (2016). https://doi.org/10.18632/oncotarget.8926
30. Yavarpour-Bali, H., Ghasemi-Kasman, M., Pirzadeh, M.: Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomedicine. 14, 4449–4460 (2019). https://doi.org/10.2147/IJN.S208332
31. Ormazabal, P., Bastías-Pérez, M., Inestrosa, N.C., Cisternas, P.: Adipokines at the Metabolic–Brain Interface: Therapeutic Modulation by Antidiabetic Agents and Natural Compounds in Alzheimer's Disease. Pharmaceuticals. 18, (2025). https://doi.org/10.3390/ph18101527
32. Choi, H.M., Doss, H.M., Kim, K.S.: Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int. J. Mol. Sci. 21, 1219 (2020). https://doi.org/10.3390/ijms21041219
33. Zhou, F., Li, X., Jiang, J., Zhang, L.: Understanding obesity–cancer crosstalk to inform the immunomodulatory roles of anti-obesity nanotherapeutics. Mater. Today Bio. 36, 102756 (2026). https://doi.org/10.1016/j.mtbio.2025.102756
34. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
35. Jouy, S.H., Mohan, S., Scichilone, G., Mostafa, A., Mahmoud, A.M.: Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines. 12, (2024). https://doi.org/10.3390/biomedicines12092129
36. Divella, R., De Luca, R., Abbate, I., Naglieri, E., Daniele, A.: Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J. Cancer. 7, 2346–2359 (2016). https://doi.org/10.7150/jca.16884
37. Barua, S., Mitragotri, S.: Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today. 9, 223–243 (2014). https://doi.org/10.1016/j.nantod.2014.04.008
38. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347–380 (2019). https://doi.org/10.1007/s40005-019-00439-x
39. Fatima, I., Khan, A., Rahdar, A., Fathi-karkan, S., Kharaba, Z., Baino, F.: Optimized mesalamine-loaded polyelectrolyte complex nanoparticles for targeted colon delivery in inflammatory bowel disease treatment: A central composite design approach. Mater. 8, 100530 (2025). https://doi.org/10.1016/j.nxmate.2025.100530
40. Ghadami, A., Fathi-karkan, S., Siddiqui, B., Gondal, S.A., Rahdar, A., Garousi, N.A., Kharaba, Z., Ghotekar, S.: Nanotechnology in Imatinib delivery: advancing cancer treatment through innovative nanoparticles. Med. Oncol. 42, 116 (2025). https://doi.org/10.1007/s12032-025-02660-1
41. Zhang, Y., Tian, J.: Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies. ACS Omega. 9, 37459–37504 (2024). https://doi.org/10.1021/acsomega.4c04573
42. Sultana, A., Zare, M., Thomas, V., Kumar, T.S.S., Ramakrishna, S.: Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Med. Drug Discov. 15, 100134 (2022). https://doi.org/10.1016/j.medidd.2022.100134
43. Patra, J.K., Das, G., Fraceto, L.F., Campos, E.V.R., Rodriguez-Torres, M. del P., Acosta-Torres, L.S., Diaz-Torres, L.A., Grillo, R., Swamy, M.K., Sharma, S., Habtemariam, S., Shin, H.-S.: Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnology. 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8
44. Bawa, I., Ugwu, O.P.-C., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
45. Chang, W., Meng, Z., Zhao, Y., Qi, Y., Li, Z., Lian, H.: Emerging Nanotechnology Strategies for Obesity Therapy. Adv. Sci. 12, e01813 (2025). https://doi.org/10.1002/advs.202501813
46. Taylor, E.B.: The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin. Sci. Lond. Engl. 1979. 135, 731–752 (2021). https://doi.org/10.1042/CS20200895

47. Savulescu-Fiedler, I., Mihalcea, R., Dragosloveanu, S., Scheau, C., Baz, R.O., Caruntu, A., Scheau, A.-E., Caruntu, C., Benea, S.N.: The Interplay between Obesity and Inflammation. Life. 14, (2024). https://doi.org/10.3390/life14070856
48. Ugwu OPC, Ugwu CN, Alum EU. Integrated approaches in nutraceutical delivery systems: optimizing ADME dynamics for enhanced therapeutic potency and clinical impact. RPS Pharm Pharmacol Rep. 2024;3(4):rqae024.
49. Eze VHU, Eze CE, Alaneme GU, Mirembe NF, Ugwu OPC, Ogenyi FC, et al. Systematic review of nanoelectronic drug delivery systems advancing technological innovation, clinical integration, and personalized therapy. Front Nanotechnol. 2026;7(1):1686599.
50. Ugwu OPC, Ogenyi FC, Basajja M, Ugwu CN, Okon MB, Ugwu JN, et al. Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. Front Drug Deliv. 2026;6:1793322.
51. Ugwu OPC, Ugwu MN, Ogenyi FC, Eze VHU, Alum EU. Nano-enhanced phytomedicine: a review of nanocarrier systems for targeted delivery of plant-derived bioactives in chronic disease therapy. Phytomedicine Plus. 2026.
52. Ugwu OPC. Pharmacogenomics and toxicogenomics in personalized public health: integrating genetic insights, emerging technologies, and global regulatory perspectives to prevent drug-related adverse events. Curr Pharmacogenomics Pers Med. 2026. doi:10.2174

CITE AS: Winniefred Nankya (2026). Nano-Enabled Regulation of Adipokines and Cytokine Signaling in Obesity-Induced Inflammatory Pathways. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):54-59.
https://doi.org/10.59298/NIJSES/2026/72.5459